Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
AstraZeneca announced the launch of Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Tagrisso was designated as a Breakthrough Therapy and approved by the Food and Drug Administration (FDA) on November 13, 2015.
RELATED: FDA Approves Tagrisso to Treat Non-Small Cell Lung Cancer
Tagrisso is an EGFR-TKI, a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations (EGFRm), and T790M, a genetic mutation responsible to EGFR-TKI treatment resistance. Its approval was based on two multicenter, single-arm, open-label clinical trials in patients with metastatic EGFR T790M mutation-positive NSCLC who had progressed on prior systemic therapy, including an EGFR TKI (Study 1 and 2).
Tagrisso is available immediately at Biologics as 40mg and 80mg tablets in 30-count bottles. Physicians may submit prescriptions to Biologics via phone [(800) 850-4306, option 2], fax [(800) 823-4506] or eScribe.
For more information visit Biologicsinc.com or Astrazeneca-us.com.
